Introduction {#sec1_1}
============

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world \[[@B1]\]. Sorafenib, an oral molecular-targeted drug, has become the standard therapy for advanced HCC (i.e., extrahepatic metastases, unresectable or not eligible for locoregional therapy) \[[@B2]\]. Sorafenib is a multiple kinase inhibitor which affects tumor proliferation and angiogenesis by inhibiting Raf-1, B-Raf kinase, vascular endothelial growth factor receptor 1, 2 and 3, platelet-derived growth factor receptor β, Flt-3 and c-KIT 2.

Two recent double-blind randomized phase III trials, the Sorafenib HCC Randomized Protocol (SHARP) \[[@B2]\] and the Asian-Pacific Trial \[[@B3]\], have shown improvement in overall survival after sorafenib treatment; in addition, sorafenib is believed to be particularly effective for distant metastasis. However, the partial response was low at 2--5%percnt;, and there were no cases of complete response (CR) among the 449 patients treated with sorafenib in these trials. Therefore, sorafenib has been considered as a disease stabilizer.

Herein, we report a very rare case treated with sorafenib for HCC with multiple lung metastases resulting in a CR that has been maintained for 48 months.

Case Report {#sec1_2}
===========

A 77-year-old Japanese female was diagnosed with chronic hepatitis C in 1990. A HCC (13 × 10 mm) was detected in segment 7/8 on a computed tomography (CT) scan and treated with percutaneous ethanol injection therapy in April 2007. Subsequently, recurrence of the HCC (23 × 13 mm) was observed in December 2010 in the same segment, and microwave coagulation therapy was performed. In April 2011, a chest X-ray image and CT scan revealed multiple lung metastases (fig. [1a](#F1){ref-type="fig"}). No brain or bone metastases could be detected.

Laboratory test results at the time of diagnosis were as follows: albumin 2.9 g/dl, aspartate aminotransferase 30 IU/l, alanine aminotransferase 15 IU/l, total bilirubin 0.5 mg/dl and prothrombin international normalized ratio 1.05. The patient had good reserve liver function with a Child-Pugh score of 6 (Child-Pugh class A) and did not have any ascites or findings of encephalopathy. Tumor markers such as α-fetoprotein (AFP; 76,170 ng/ml), the lens culinaris agglutinin-reactive fraction of AFP (7.5%percnt;) and des-γ-carboxyprothrombin (DCP; 63,400 mAU/ml) were elevated. Sorafenib administration was initiated at a reduced dose of 400 mg/day, because of the patient\'s advanced age and low body mass index (BMI) of 19.7.

After 4 months of sorafenib administration, the tumor markers decreased to normal levels (AFP 7.5 ng/ml, DCP 30 mAU/ml), and the metastatic lung lesions had disappeared (fig. [1b](#F1){ref-type="fig"}). We considered that the patient had achieved a CR according to the RECIST evaluation. The patient continues to be treated with sorafenib at a reduced dose of 400 mg/day without adverse effects and is still maintaining a CR.

Discussion {#sec1_3}
==========

The present patient represents a rare case involving multiple lung metastases, confirmed on the basis of imaging and tumor marker levels, who achieved a CR after treatment with sorafenib. Furthermore, it was unusual because the patient has maintained this CR for 48 months and has continued sorafenib treatment without adverse effects. There are 2 important points to note in our case: (1) the achievement of a CR and (2) long-term maintenance of the CR.

Sorafenib is usually used for disease stabilization, and its response rate is \<9%percnt;. In a retrospective study that compared sorafenib responders (CR and partial response) and nonresponders (stable disease, progressive disease and nonprogressive disease), multiple lung metastases were frequently observed in responders to sorafenib \[[@B4]\]. Therefore, sorafenib seems to be effective in the treatment of extrahepatic metastasis, especially lung metastasis. Shiba et al. \[[@B5]\] reported that significant factors in their 18 Japanese cases involving a CR were sex (female), low body weight (\<59 kg), early clinical stage and use of a small initial dose. The clinical characteristics of the 12 reported cases and our case that achieved a CR as a result of sorafenib treatment are detailed in table [1](#T1){ref-type="table"} \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15], [@B16], [@B17]\]. There were 6 (46%percnt;) lung metastasis cases. The data suggest that sorafenib is useful in the treatment of lung metastasis. Intrahepatic tumor stage seems unrelated to the rate of CR, because 8 out of 13 cases were at stage T3--4. AFP levels decreased by \>20%percnt; in all cases presented in table [1](#T1){ref-type="table"}, but 9 out of 13 cases had an initial AFP level of ≥400 ng/dl. This indicates that the AFP response is a good prognostic factor regarding CR and also that it is possible to achieve a CR regardless of the initial AFP levels.

The number of males and females was 11 and 2, respectively. Interestingly, only 4 out of 13 cases had commenced treatment with sorafenib at a dose of 400 mg/day (table [1](#T1){ref-type="table"}). Elucidation of the characteristics of HCC patients who attained a CR after sorafenib treatment allows prediction of efficacy and survival outcome before the initiation of treatment. However, populations of patients who have achieved a CR are too small for definitive conclusions to be made. Further evaluation in future clinical studies is required.

Five out of 13 cases had maintained a CR for \>10 months (table [1](#T1){ref-type="table"}). Two among these 5 cases exhibited multiple lung metastases. These findings suggest that a patient who has multiple lung metastases can be expected to achieve a long-term CR. It has been controversial as to whether or not sorafenib treatment should be continued after the diagnosis of a CR. In a previous study, 188 patients who had undergone sorafenib monotherapy were analyzed, and it was reported that patients who received sorafenib for \>90 days showed a favorable outcome \[[@B18]\]. In fact, 3 out of 5 long-term CR patients detailed in table [1](#T1){ref-type="table"} continued sorafenib administration. Consequently, continuation of sorafenib treatment may be important in maintaining a long-term CR. The tolerability of sorafenib must be a limitation regarding continuation of the treatment. Actually, in most patients, the initial dose of sorafenib had been reduced because of adverse effects (table [1](#T1){ref-type="table"}). In the GIDEON study \[[@B19]\], the advantage of using a sorafenib dose of 800 mg/day had been demonstrated. However, a randomized control study carried out by the SOraFenib Italian Assessment (SOFIA) group compared initial doses of 400 mg/day and 800 mg/day. It was found that the therapy group that received the lower dose of 400 mg/day had a longer median survival time \[[@B20]\]. In our case, we started sorafenib treatment at a reduced dose of 400 mg/day because the patient was elderly and had a low BMI. As mentioned, the patient has been maintained on the same dose for \>3 years without adverse effects.

In conclusion, multiple lung metastases and low body weight seem to be the characteristics required for the achievement of a long-term CR. The reason for the superiority regarding the use of a reduced initial dose of 400 mg/day remains unclear. However, our case suggests the possibility of achieving a long-term CR as a result of continuation of treatment with this dose of sorafenib. The limitation of this report is that the periods over which a CR was sustained in the cases detailed in table [1](#T1){ref-type="table"} might be underestimates; this is because many of the patients would have continued to maintain their CR after the date on which their data were published. It remains important to accumulate and carefully analyze long-term CR cases in order to fully investigate the prognostic factors regarding sorafenib.

Conclusion {#sec1_4}
==========

We have reported a case of innumerable multiple lung metastases of HCC keeping a CR for 48 months.
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![Chest CT images. **a** CT image at the initiation of sorafenib administration. Innumerable multiple lung metastases were revealed in both lungs. **b** CT image 4 months after sorafenib treatment. The multiple lung metastases disappeared in both lungs after sorafenib treatment.](crg-0009-0285-g01){#F1}

###### 

Complete response in HCC patients treated with sorafenib

  First author          Age, years/sex   Etiology           Intrahepatic tumor stage (T stage)   Extrahepatic spread   Time to cessation   Time to CR   Administration period after CR, months   Reason of cessation   CR sustained period, months   AFP, ng/ml   AFP-L3, %percnt;   DCP, mAU/ml   Sorafenib initial dose, mg/day   Maintenance dose, mg/day
  --------------------- ---------------- ------------------ ------------------------------------ --------------------- ------------------- ------------ ---------------------------------------- --------------------- ----------------------------- ------------ ------------------ ------------- -------------------------------- --------------------------
  Chelis \[[@B6]\]      69/M             HBV, HIV           3                                    lymph node            none                10 months    --                                       --                    06                            0000.--      0--                0000.--       800                              400
                                                                                                                                                                                                                                                                                                                                    
  So \[[@B7]\]          78/M             Hemochro-matosis   3                                    lung                  6 months            05 months    1                                        clinical              06                            13,599       0--                0000.--       800                              800
                                                                                                                                                                                                                                                                                                                                    
  Sacco \[[@B8]\]       84/M             HCV                3                                    none                  none                06 months    --                                       --                    06                            00.353       0--                0000.--       800                              800
                                                                                                                                                                                                                                                                                                                                    
  Yeganeh \[[@B9]\]     54/M             HBV                0                                    lung                  none                18 months    --                                       --                    07                            0000.1.3     0--                0000.--       800                              200
                                                                                                                                                                                                                                                                                                                                    
  Kim \[[@B10]\]        66/M             alcohol            4                                    lymph node            12 months           06 months    6                                        financial             08                            02,795       0--                0000.--       800                              400
                                                                                                                                                                                                                                                                                                                                    
  Inuzuka \[[@B11]\]    76/F             HCV                0                                    lung                  4 months            03 months    1                                        liver dysfunction     08                            06,952       0--                00.187        400                              400
                                                                                                                                                                                                                                                                                                                                    
  Hagihara \[[@B12]\]   65/M             HCV                0                                    lung                  21 days             03 months    0                                        ascites               08                            55,607       0--                11,302        400                              400
                                                                                                                                                                                                                                                                                                                                    
  Mizukami \[[@B13]\]   69/M             HCV                0                                    lymph node            11 days             03 months    0                                        hand foot syndrome    09                            000.25.1     22.8               000.65        800                              400
                                                                                                                                                                                                                                                                                                                                    
  Kee \[[@B14]\]        74/M             unknown            4                                    none                  none                09 months    --                                       --                    10                            33,058       0--                0000.--       800                              200
                                                                                                                                                                                                                                                                                                                                    
  Kudo \[[@B15]\]       68/M             HBV                3                                    lung                  none                02 months    --                                       --                    12                            18,775       68.1               26,021        800                              400
                                                                                                                                                                                                                                                                                                                                    
  Shiozawa \[[@B16]\]   68/M             HCV                4                                    none                  2.4 years           02 years     4                                        patient\'s request    16                            04,773       60.5               17,400        800                              400
                                                                                                                                                                                                                                                                                                                                    
  Wang \[[@B17]\]       74/M             HCV                4                                    none                  8 months            08 months    0                                        nausea, vomiting      16                            03,300       0--                0000.--       400                              400
                                                                                                                                                                                                                                                                                                                                    
  Our case              77/F             HCV                0                                    lung                  none                03 months    --                                       --                    45                            76,170       07.5               63,400        400                              400

M = Male, F = female, HBV = hepatitis B virus, HIV = human immunodeficiency virus, HCV = hepatitis C virus.
